UGT1A Cancer Research Results

UGT1A, UGT1A / glucuronidation pathway: Click to Expand ⟱
Source:
Type:

UGT1A1 - UDP Glucuronosyltransferase Family 1 Member A1

Abbreviation: UGT1A1

Type: Phase II drug-metabolizing enzyme / glucuronosyltransferase

Function: UGT1A1 catalyzes glucuronidation of bilirubin and numerous endogenous and xenobiotic compounds, increasing their water solubility and facilitating elimination. It also contributes to metabolism of several anticancer drugs and influences irinotecan toxicity through glucuronidation of SN-38.

Cancer: ↕ Context-dependent. UGT1A1 expression and activity vary substantially between tumor types. Increased activity can enhance detoxification of carcinogens but can also reduce exposure to susceptible anticancer agents, whereas reduced activity can alter carcinogen and drug metabolism.

UGT1A3 - UDP Glucuronosyltransferase Family 1 Member A3

Abbreviation: UGT1A3

Type: Phase II drug-metabolizing enzyme / glucuronosyltransferase

Function: UGT1A3 glucuronidates bile acids, fatty acids, steroid-related compounds, drugs, and other lipophilic substrates. It is expressed predominantly in liver and contributes to xenobiotic and endogenous lipid metabolism.

Cancer: ↕ Context-dependent. Tumor-associated expression varies by tissue and may influence cancer risk, lipid and hormone metabolism, and intratumoral drug clearance.

UGT1A6 - UDP Glucuronosyltransferase Family 1 Member A6

Abbreviation: UGT1A6

Type: Phase II drug-metabolizing enzyme / glucuronosyltransferase

Function: UGT1A6 glucuronidates numerous phenolic compounds, xenobiotics, environmental chemicals, and therapeutic drugs and contributes to their detoxification and elimination.

Cancer: ↕ Context-dependent. UGT1A6 is highly expressed in several tumor types and can influence intratumoral drug metabolism and carcinogen detoxification. Its prognostic significance varies substantially by cancer type.

UGT1A7 - UDP Glucuronosyltransferase Family 1 Member A7

Abbreviation: UGT1A7

Type: Phase II drug-metabolizing enzyme / glucuronosyltransferase

Function: UGT1A7 is an extrahepatic glucuronosyltransferase involved in detoxification of dietary and environmental xenobiotics, including potentially carcinogenic compounds, particularly in gastrointestinal tissues.

Cancer: ↕ Context-dependent. UGT1A7 activity can protect against carcinogen exposure through glucuronidation, while altered expression or genetic variants have been associated with cancer susceptibility and tumor-specific metabolic phenotypes.

UGT1A8 - UDP Glucuronosyltransferase Family 1 Member A8

Abbreviation: UGT1A8

Type: Phase II drug-metabolizing enzyme / glucuronosyltransferase

Function: UGT1A8 is predominantly an extrahepatic gastrointestinal enzyme that glucuronidates dietary compounds, drugs, flavonoids, and other xenobiotics and contributes to intestinal detoxification.

Cancer: ↕ Context-dependent. Altered UGT1A8 expression can affect local carcinogen metabolism, dietary bioactive compounds, and anticancer drug exposure, with direction varying by tumor type.

UGT1A9 - UDP Glucuronosyltransferase Family 1 Member A9

Abbreviation: UGT1A9

Type: Phase II drug-metabolizing enzyme / glucuronosyltransferase

Function: UGT1A9 is highly expressed in liver and kidney and glucuronidates numerous drugs, phenolic compounds, fatty-acid derivatives, and endogenous metabolites.

Cancer: ↕ Context-dependent. UGT1A9 is highly expressed in several cancers arising from drug-metabolizing tissues and can substantially modify intratumoral drug clearance and metabolic signaling.

UGT1A10 - UDP Glucuronosyltransferase Family 1 Member A10

Abbreviation: UGT1A10

Type: Phase II drug-metabolizing enzyme / extrahepatic glucuronosyltransferase

Function: UGT1A10 is predominantly expressed in extrahepatic tissues, particularly the gastrointestinal tract, and glucuronidates dietary compounds, drugs, phenols, flavonoids, and other xenobiotics.

Cancer: ↕ Context-dependent. UGT1A10 is highly expressed in several gastrointestinal and epithelial cancers and can influence carcinogen detoxification, bioactive compound metabolism, and tumor exposure to susceptible drugs.
Scientific Papers found: Click to Expand⟱
7769- IBC,    Potential Determinants for Metabolic Fates and Inhibitory Effects of Isobavachalcone Involving in Human Cytochrome P450, UDP-Glucuronosyltransferase Enzymes, and Efflux Transporters
- in-vivo, NA, NA
*AntiCan↑, *AntiAg↑, *AntiFungal↑, CYP2C9↓, UGT1A↓, CYP2D6↓, CYP2E1↓,
7752- ISL,    Isoliquiritigenin showed strong inhibitory effects towards multiple UDP-glucuronosyltransferase (UGT) isoform-catalyzed 4-methylumbelliferone (4-MU) glucuronidation
- in-vitro, Nor, NA
*UGT1A↓,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

CYP2D6↓, 1,   UGT1A↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

CYP2E1↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

CYP2C9↓, 1,  
Total Targets: 4

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

UGT1A↓, 1,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiFungal↑, 1,  
Total Targets: 4

Scientific Paper Hit Count for: UGT1A, UGT1A / glucuronidation pathway
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1691  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page